uniQure offers a cash-backed, high-risk regulatory option on AMT-130, with a May 1, 2027 FDA decision that could unlock substantial Huntington’s disease upside—or leave the company primarily a HEMGENIX royalty holder.
Overview
uniQure N.V. is a commercial and clinical-stage gene-therapy company whose model combines royalties and manufacturing income from HEMGENIX with development of wholly owned AAV candidates. HEMGENIX, licensed to CSL Behring, generated $14.6 million in royalties in the first nine months of 2026; uniQure retained higher royalty tiers and up to $1.3 billion in potential milestones. The central asset is AMT-130 for Huntington’s disease, an AAV5 gene-silencing therapy whose BLA received FDA Priority Review, with a May 1, 2027 PDUFA date. The company reported Q3 2026 revenue of $5.196 million, up 40.4% year over year but 15.7% below consensus, and a $61.22 million net loss. Its $768.4 million cash and securities balance is expected by management to fund operations into 2030. **The investment case is dominated by the binary AMT-130 decision and the potential to become the first disease-modifying Huntington’s therapy.** At approximately $21.70 per share, the report’s probability-weighted five-year target is $55.17, while its scenarios range from $1.54 to $134.77. Near-term catalysts include the FDA Advisory Committee process and confirmatory-trial screening; material risks include the 48-month durability data and surgical commercialization requirements.